InflaMix Identifies CAR-T Recipients with a Preinfusion Inflammatory Profile Indicative of High Risk for CAR-T Treatment Failure By Ogkologos - May 5, 2025 391 0 Facebook Twitter Google+ Pinterest WhatsApp A valuable tool for point-of-care clinical decision-making in patients with non-Hodgkin lymphoma Source RELATED ARTICLESMORE FROM AUTHOR FDA Grants Traditional Approval to Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive Solid Tumours ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC MOST POPULAR Fostering Black leadership in cancer research July 20, 2023 FDA Approves Neoadjuvant/Adjuvant Nivolumab for Resectable Non-Small Cell Lung Cancer October 15, 2024 New on NCI’s Websites for April 2024 April 12, 2024 Pine Trees or COVID? September 2, 2020 Load more HOT NEWS Judge Rules That 3-Year-Old Child With Leukemia Must Get Chemo Against... ‘Family Haven’ Gives Homeless Parents & Their Kids Hope And A... EMA Pharmacovigilance Risk Assessment Committee Advice on Safety-Related Aspects of the... FDA Grants Accelerated Approval to Pembrolizumab for HER2-positive Gastric Cancer
